These findings implicate a functional interaction between TREM2, CD33, and PU.1 in monocytes, and suggest that modulating signaling downstream of TREM2 may provide a mechanism to alter functional deficits associated with these AD risk variants. This evidence concerns the gene TREM2 and Alzheimer disease.